Short-term OS As a Surrogate Endpoint for 5-year OS in Nasopharyngeal Carcinoma in Non-endemic Area

Overview

Journal World J Surg Oncol

Publisher Biomed Central

Specialties General Surgery
Oncology

Date 2024 Jul 10

PMID 38987785

Authors

Ying Guan

Lu Han

Han-Yin Luo

Bin-Bin Yu

Shi-Ting Huang

Affiliations

Soon will be listed here.

Abstract

Purpose: To address this evidence gap and validate short-term OS at less than 5 years as a reliable surrogate endpoint for 5-year OS.

Methods: We analyzed data from the Surveillance, Epidemiology, and End Results (SEER) database, focusing on non-metastatic NPC patients diagnosed between 2010 and 2015. Patients were categorized into radiotherapy and chemoradiotherapy groups.

Results: This retrospective study examined 2,047 non-metastatic NPC patients. Among them, 217 received radiotherapy, and 1,830 received chemoradiotherapy. Our analysis results indicated that the 4-year OS may serve as a reliable surrogate endpoint for patients with AJCC clinical stage I (80 vs. 78%, P = 0.250), regardless of the treatment received. Specifically, in the radiotherapy group, patients with stage I, T0-T1, and N0 NPC showed similar OS rates at 4 and 5 years (83 vs. 82%, P = 1.000; 78 vs. 76%, P = 0.250; 78 vs. 77%, P = 0.500, respectively). Similarly, patients with stage II-IV, T2-T4, and N1-3 NPC showed no significant difference in OS rates between 3 and 5 years (57 vs. 51%, P = 0.063; 52 vs. 46%, P = 0.250; 54 vs. 46%, P = 0.125, respectively) in the radiotherapy group. In the chemoradiotherapy group, only the 3-year OS rate did not significantly differ from that at 5 years in stage I patients (79vs. 72%, P = 0.063).

Conclusions: Our study suggests that short-term surrogate endpoints may be valuable for evaluating 5-year OS outcomes in NPC patients in non-endemic areas.

References

Paiar F, Di Cataldo V, Zei G, Monteleone Pasquetti E, Cecchini S, Meattini I . Role of chemotherapy in nasopharyngeal carcinoma. Oncol Rev. 2015; 6(1):e1. PMC: 4419643. DOI: 10.4081/oncol.2012.e1. View

Zhou S, Chen C, Liu S, Tao Y, Chang H, Wang X . Surrogate endpoints shortening the therapeutic evaluation duration for different subgroups of patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy: A retrospective analysis of 830 patients stratified by the 8th edition.... J Cancer. 2018; 9(18):3352-3360. PMC: 6160691. DOI: 10.7150/jca.25530. View

Chang E, Ye W, Zeng Y, Adami H . The Evolving Epidemiology of Nasopharyngeal Carcinoma. Cancer Epidemiol Biomarkers Prev. 2021; 30(6):1035-1047. DOI: 10.1158/1055-9965.EPI-20-1702. View

Pan X, Li L, Qu S, Chen L, Liang S, Zhu X . The efficacy of chemotherapy in survival of stage II nasopharyngeal carcinoma. Oral Oncol. 2019; 101:104520. DOI: 10.1016/j.oraloncology.2019.104520. View

Carol M, Grant 3rd W, Pavord D, Eddy P, Targovnik H, Butler B . Initial clinical experience with the Peacock intensity modulation of a 3-D conformal radiation therapy system. Stereotact Funct Neurosurg. 1996; 66(1-3):30-4. DOI: 10.1159/000099664. View

Chen Y, Sun Y, Chen L, Mao Y, Tang L, Li W . Surrogate endpoints for overall survival in combined chemotherapy and radiotherapy trials in nasopharyngeal carcinoma: Meta-analysis of randomised controlled trials. Radiother Oncol. 2015; 116(2):157-66. DOI: 10.1016/j.radonc.2015.07.030. View

Ou S, Zell J, Ziogas A, Anton-Culver H . Epidemiology of nasopharyngeal carcinoma in the United States: improved survival of Chinese patients within the keratinizing squamous cell carcinoma histology. Ann Oncol. 2006; 18(1):29-35. DOI: 10.1093/annonc/mdl320. View

Ecker B, Lee J, Saadat L, Aparicio T, Buisman F, Balachandran V . Recurrence-free survival versus overall survival as a primary endpoint for studies of resected colorectal liver metastasis: a retrospective study and meta-analysis. Lancet Oncol. 2022; 23(10):1332-1342. DOI: 10.1016/S1470-2045(22)00506-X. View

Yang X, Zhang L, Kou J, Zhou G, Wu C, Sun Y . Cisplatin-based concurrent chemoradiotherapy improved the survival of locoregionally advanced nasopharyngeal carcinoma after induction chemotherapy by reducing early treatment failure. BMC Cancer. 2022; 22(1):1230. PMC: 9706941. DOI: 10.1186/s12885-022-10237-8. View

10.

Chen C, Yi W, Gao J, Li X, Shen L, Li B . Alternative endpoints to the 5-year overall survival and locoregional control for nasopharyngeal carcinoma: A retrospective analysis of 2,450 patients. Mol Clin Oncol. 2014; 2(3):385-392. PMC: 3999144. DOI: 10.3892/mco.2014.262. View

11.

Nordlinger B, Sorbye H, Glimelius B, Poston G, Schlag P, Rougier P . Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013; 14(12):1208-15. DOI: 10.1016/S1470-2045(13)70447-9. View

12.

Liu P, Xue X, Zhang C, Zhou H, Ding Z, Jiang Y . Prognostic factor analysis in patients with early-stage nasopharyngeal carcinoma in the USA. Future Oncol. 2023; 19(15):1063-1072. DOI: 10.2217/fon-2022-0609. View

13.

Rotolo F, Pignon J, Bourhis J, Marguet S, Leclercq J, Ng W . Surrogate End Points for Overall Survival in Loco-Regionally Advanced Nasopharyngeal Carcinoma: An Individual Patient Data Meta-analysis. J Natl Cancer Inst. 2016; 109(4). PMC: 6059121. DOI: 10.1093/jnci/djw239. View

14.

Lin J, Jan J, Hsu C, Liang W, Jiang R, Wang W . Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol. 2003; 21(4):631-7. DOI: 10.1200/JCO.2003.06.158. View

15.

Luo W . Nasopharyngeal carcinoma ecology theory: cancer as multidimensional spatiotemporal "unity of ecology and evolution" pathological ecosystem. Theranostics. 2023; 13(5):1607-1631. PMC: 10086202. DOI: 10.7150/thno.82690. View

16.

Wang C, Yang C, Yeh S, Huang C, Hwang T, Yang C . The Impact of Insurance and Marital Status on Survival in Patients with Nasopharyngeal Carcinoma. Biology (Basel). 2020; 9(4). PMC: 7235887. DOI: 10.3390/biology9040084. View

17.

Guo R, Wu H, Wang J, Lian C, He Z, Zhang W . Lymph Node Status and Outcomes for Nasopharyngeal Carcinoma According to Histological Subtypes: A SEER Population-Based Retrospective Analysis. Adv Ther. 2019; 36(11):3123-3133. DOI: 10.1007/s12325-019-01100-7. View

18.

Chen P, Li W, Wang J, Jiang Y, Wu P, Chen T . Association between MTHFR gene polymorphisms (C677T, A1298C) and genetic susceptibility to prostate cancer: a meta-analysis. Genet Mol Res. 2016; 14(4):19191-202. DOI: 10.4238/2015.December.29.29. View

19.

Peng G, Wang T, Yang K, Zhang S, Zhang T, Li Q . A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. Radiother Oncol. 2012; 104(3):286-93. DOI: 10.1016/j.radonc.2012.08.013. View

20.

. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344(8934):1383-9. View